Drug intelligence / Profile preview

HTPEP-004

Development stage: Preclinical
Lead developer: Chengdu Huitai Biomedical
Modality: Peptides

Overview

HTPEP-004 is a peptide-based therapeutic candidate developed by Chengdu Huitai Biopharmaceutical for the treatment of skin fibrosis. It functions by targeting and inhibiting Transforming Growth Factor-beta 1 (TGF-β1), a potent profibrotic cytokine that plays a central role in the activation of myofibroblasts and the accumulation of extracellular matrix components. By antagonizing TGF-β1 signaling, HTPEP-004 aims to prevent or reverse the pathological scarring and tissue stiffening characteristic of fibrotic skin disorders. The drug is currently in the preclinical stage of development.

Targets

CD36 (CD36 antigen)

Beyond the preview

Go deeper on HTPEP-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTPEP-004.

Explore the full profile